InMed Pharmaceuticals Regains Nasdaq Compliance, Averting Delisting Threat
INM has more than doubled off its 52-week low of $0.575.
Summary
InMed Pharmaceuticals announced it has regained compliance with Nasdaq's minimum bid price rule, removing the immediate threat of delisting.
Key Events · Corporate Governance and Compliance · INM
-
Regains Nasdaq Bid Price Compliance
The company received notice from Nasdaq on June 3, 2026, confirming its common shares traded above $1.00 for 10 consecutive business days (May 19 - June 2, 2026).
-
Delisting Threat Removed
This action resolves the previously disclosed non-compliance with Nasdaq Listing Rule 5550(a)(2), which had been issued on March 27, 2026.
-
Supports Pending Merger
Maintaining Nasdaq listing is crucial for the successful completion of the recently announced all-stock merger with Mentari Therapeutics.
Analysis · INM · Life Sciences
This filing reports that InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, removing an immediate delisting risk. This is a critical positive development, especially given the company's recent going concern warning and its pending all-stock merger with Mentari Therapeutics. Maintaining Nasdaq listing is essential for the merger's completion and for investor confidence.
At the time of this filing, INM was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.58 to $5.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.